PMID- 37273251
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230606
IS  - 1948-9358 (Print)
IS  - 1948-9358 (Electronic)
IS  - 1948-9358 (Linking)
VI  - 14
IP  - 5
DP  - 2023 May 15
TI  - Efficacy of multigrain supplementation in type 2 diabetes mellitus: A pilot study 
      protocol for a randomized intervention trial.
PG  - 606-616
LID - 10.4239/wjd.v14.i5.606 [doi]
AB  - BACKGROUND: Uncontrolled type 2 diabetes mellitus (T2DM) may lead to 
      microvascular complications (nephropathy, retinopathy, and neuropathy) and 
      cardiovascular diseases. The beta-glucan content in grains has the potential to 
      improve insulin sensitivity, lowering postprandial glucose response and reducing 
      inflammation degrees. A proper combination of grains not only satisfies human 
      body's need, but also provides essential and reasonable nutritional contents. 
      However, no trial has been conducted to evaluate the roles of multigrain in T2DM. 
      AIM: To determine the efficacy of multigrain supplementation among T2DM patients. 
      METHODS: From October 2020 to June 2021, a total of 50 adults living with T2DM, 
      who were receiving standard diabetes care at Day Care Clinic, were randomized 
      into either a supplementation group or a control group. The supplementation group 
      received twice daily 30 g multigrain supplement (equivalent to 3.4 g beta-glucan) 
      with standard medication for 12 wk, while the control group was prescribed with 
      standard medication. Parameters such as glycemic control (HbA1c, FPG, and 
      HOMO-IR), cardiometabolic profile (lipid profile, renal function test, and liver 
      function test), oxidative stress status, nutritional status, and quality of life 
      (QoL) were assessed at two time points: Baseline and the end of the treatment 
      period (week 12). RESULTS: The primary outcomes were the mean difference of 
      glycated haemoglobin (%), fasting plasma glucose, and serum insulin as 
      intervention effects. Secondary outcomes included the measurement of 
      cardiometabolic profile, antioxidative and oxidative stress status, nutritional 
      status indices, and QoL. Tertiary outcomes involved the determination of safety 
      and tolerability, and supplementation compliance. CONCLUSION: The present 
      clinical trial will reveal the effectiveness of multigrain supplementation among 
      T2DM patients for the improvement of diabetes management.
CI  - (c)The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Mohd Ariffin, Nur Anis
AU  - Mohd Ariffin NA
AD  - Food Technology Division, School of Industrial Technology, Universiti Sains 
      Malaysia, Gelugor 11800, Pulau Pinang, Malaysia.
FAU - Mohd Sopian, Mastura
AU  - Mohd Sopian M
AD  - Oncology and Radiological Sciences Cluster, Advanced Medical and Dental 
      Institute, Universiti Sains Malaysia, Bertam 13200, Pulau Pinang, Malaysia.
FAU - Lee, Lai Kuan
AU  - Lee LK
AD  - Food Technology Division, School of Industrial Technology, Universiti Sains 
      Malaysia, Gelugor 11800, Pulau Pinang, Malaysia. l.k.lee@usm.my.
LA  - eng
PT  - Clinical Trial
PL  - United States
TA  - World J Diabetes
JT  - World journal of diabetes
JID - 101547524
PMC - PMC10236996
OTO - NOTNLM
OT  - Beta-glucan
OT  - Clinical trial
OT  - Glycemic control
OT  - Multigrain
OT  - Type 2 diabetes mellitus
COIS- Conflict-of-interest statement: (Oat King(R)) was funded by TG Ocean Health Food 
      Industries Sdn Bhd to Lai Kuan Lee. Nevertheless, the funder has no role in the 
      conduct of the research, including the study design, data collection, analysis, 
      and interpretation, preparation of the article, and in the decision to submit the 
      article for publication. Mohd Ariffin NA and Mohd Sopian M declare no competing 
      interest.
EDAT- 2023/06/05 13:04
MHDA- 2023/06/05 13:05
PMCR- 2023/05/15
CRDT- 2023/06/05 11:44
PHST- 2022/12/23 00:00 [received]
PHST- 2023/03/02 00:00 [revised]
PHST- 2023/04/10 00:00 [accepted]
PHST- 2023/06/05 13:05 [medline]
PHST- 2023/06/05 13:04 [pubmed]
PHST- 2023/06/05 11:44 [entrez]
PHST- 2023/05/15 00:00 [pmc-release]
AID - 10.4239/wjd.v14.i5.606 [doi]
PST - ppublish
SO  - World J Diabetes. 2023 May 15;14(5):606-616. doi: 10.4239/wjd.v14.i5.606.